184 results on '"Burattini, Luciano"'
Search Results
2. Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus
3. Conditional Survival of Patients Treated With First-Line Chemotherapy for Metastatic Urothelial Cancer
4. Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma
5. Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients
6. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma
7. Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectives
8. Standard vs Adapted Sunitinib Regimen in Elderly Patients With Metastatic Renal Cell Cancer: Results From a Large Retrospective Analysis
9. Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer
10. Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma
11. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy
12. Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors
13. High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer
14. Patterns of progression of patients with high-volume metastatic castration-sensitive prostate cancer treated with early docetaxel chemotherapy: The LONGITUDE observational study.
15. Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside
16. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma
17. Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma
18. Level IV tumor thrombus in non-metastatic renal cell cancer? No, thanks. Level II is better. Lessons learned from a case report
19. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials
20. Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor
21. Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma
22. Effects of Switching from Tamoxifen to Anastrozole on Tamoxifen-Related Endocrine Symptoms and Quality of Life: In Early Breast Cancer Patients
23. Phase II Study of Oxaliplatin and Gemcitabine Salvage Chemotherapy in Patients with Cisplatin-Refractory Nonseminomatous Germ Cell Tumor
24. 07 - THE NEGATIVE PROGNOSTIC ROLE OF OPIOIDS IN PATIENTS WITH NSCLC TREATED WITH IMMUNOTHERAPY
25. Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma
26. PD62-05 NEOADJUVANT CHEMOTHERAPY IN MUSCLE-INVASIVE BLADDER CANCER: DIFFERENCES IN CLINICAL AND PATHOLOGICAL RESPONCE
27. Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges
28. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
29. Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma
30. Prostate cancer: from Gleason scoring to prognostic grade grouping
31. Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients
32. Role of STAT3 pathway in genitourinary tumors
33. ACTH 1–17 effects in oncology
34. Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma
35. Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder
36. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma
37. Inside the 2015 ASCO Genitourinary Cancers Symposium
38. Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis
39. Correlation between everolimus discontinuation or dose reduction induced by stomatitis or cutaneous toxicity and clinical outcome in patients with metastatic renal cell carcinoma.
40. Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors
41. High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer
42. Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting
43. High neutrophil to lymphocyte ratio persistent during first-line chemotherapy to predict clinical outcome in patients with advanced urothelial cancer.
44. Prognostic factors in patients with pancreatic metastases from renal cell carcinoma (PM-RCC): Room for thinking about the role of surgery?
45. VEGF and VEGFRs polymorphisms analysis in advanced renal cell carcinoma tissues: Is heterogeneity ever the answer?
46. [11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas
47. Correlation of distinctive angiogenetic profiles with clinical outcome for different treatment sequences in mRCC.
48. Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside
49. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials
50. Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.